Sequence: WEAKLAKALAKALAKHLAKALAKALKA
| Experiment Id | EXP000860 |
|---|---|
| Paper | Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold |
| Peptide | KALA |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | lipoplex (ionizable lipid LNP + CPP + mRNA) |
| Formulation Components | Main lipid EPC; DOPE; cholesterol (3:4:3 molar). Surface peptide STR-KALA. |
| Size Nm | 134.00 |
| Zeta Mv | 31.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | murine bone marrow-derived dendritic cells (BMDCs, primary) |
| Animal Model | |
| Administration Route | |
| Output Type | reporter protein expression (luciferase) |
| Output Value | |
| Output Units | |
| Output Notes | Luc-mRNA lipoplex; BMDCs transfected (0.4 µg mRNA / 4×10^5 cells); luciferase measured 6 h post-transfection (Fig. 2). |
| Toxicity Notes | No dedicated cytotoxicity assay reported; cytokine production measured (IFN-β, IL-6). |
| Curation Notes |